ArticleDrug and alcohol dependence2025
Polysubstance use in pregnancy: Findings from a population-based cross-sectional cohort study of pregnant women with opioid use.
Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposePrior work suggests that pregnant women with opioid use may be especially likely to use multiple substances. Given the risks of substance use and polysubstance use during pregnancy, this study explored rates and covariates of polysubstance use in women with and without opioid use during pregnancy. PROCEDURES: We conducted a population-based cross-sectional cohort study of pregnancies delivering at or after 35 weeks' gestation in 15 Kaiser Permanente Northern California (KPNC) hospitals. Among 369,199 women delivering past 35 weeks' gestation between 2010 and 2019, we extracted data on substance use, lifetime psychiatric diagnoses, diagnoses of opioid use disorder (OUD) and depression, and sociodemographic characteristics
findingsCompared to women without opioid use during pregnancy (n = 361,144), those with opioid use during pregnancy (n = 8055) were significantly more likely to use all other classes of substances (p < 0.001) and significantly more likely to have lifetime and maternal depression diagnoses (p < 0.001). Additionally, those with opioid use during pregnancy had significantly higher neighborhood deprivation index scores, were significantly more likely to be insured by Medicare or Medicaid, had lower educational attainment, and were more likely to identify as Black (p < 0.001). Comparisons by opioid use type suggest that those with heroin use had heavier patterns of polysubstance use compared to those with methadone, buprenorphine or prescribed opioid medication use (p < 0.001).
conclusionsFindings shed light on the prevalence of polysubstance use among pregnant women with opioid use (15.5 % used cannabis, 9.3 % used tobacco, 5.2 % used benzodiazepines, 2.8 % used methamphetamines, 1.6 % used barbiturates and 1.0 % used cocaine), and highlight key differences in drug exposure between pregnant women with prescribed opioid use versus MOUD use versus heroin use (namely lower rates of polysubstance use among pregnant women with MOUD exposure compared to those with heroin use). Together, findings support a potentially protective role of methadone and buprenorphine for this population with regards to polysubstance use, and a need for more integrated psychiatric care among this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.